Dow, S&P 500 set record high closes ahead of holiday

Biogen (BIIB) PT Lowered to $355 at Leerink Partners on Reduced Aducanumab Probability of Success

Leerink Partners analyst Geoffrey Porges reduced Aducanumab probability of success and cut his price target on Biogen (NASDAQ: BIIB) price target of $355.00 (from $365.00) after Lilly announced on Wednesday that the EXPEDITION 3 study of solanezumab (sola) in mild Alzheimer's patients did not meet its primary or secondary... More

Eli Lilly (LLY) PT Cut to $92 at Leerink Partners

Leerink Partners analyst Seamus Fernandez lowered its price target on Eli Lilly (NYSE: LLY) to $92.00 (from $102.00) following the Sola failure but maintains a Outperform rating.

Fernandez commented, "LLY announced that solanezumab did not meet the primary endpoint in the Phase 3 EXPEDITION 3 study. Per our follow up... More

BMO Capital Downgrades Eli Lilly (LLY) to Market Perform Following Sola's Failure

BMO Capital downgraded Eli Lilly (NYSE: LLY) from Outperform to Market Perform with a price target of $64.00 (from $91).

Analyst Alex Arfaei commented, "We believe Solas failure in EXPEDITION-3 is clearly a meaningfully negative event as it significantly lowers Lillys long-term growth... More

Baird Sees Minimal Read Through for Axovant (AXON) on Lilly's Sola Failure

Baird analyst Brian Skorney came out to defend Axovant Sciences (NYSE: AXON), which was weaker on Lilly's solanezumab failure. The analyst sees no change for AXON and maintained an Outperform rating and price target of $29.

Skorney commented, "The Alzheimer's field was... More

Mizuho Securities Reiterates Neutral on Urban Outfitters (URBN) Following EPS 3Q Miss

Mizuho Securities reiterated a Neutral rating and $32.00 price target on Urban Outfitters, Inc. (NASDAQ: URBN) following the company's 3Q earnings report. URBN reported 3Q EPS of $0.40, compared to $0.42 LY. EPS was below consensus $0.44 estimate.

Analyst Betty Chen commented, "We are lowering... More